February 13, 2020
Video
Andrew Kuykendall, MD, discusses the current treatment landscape for the patients with myelofibrosis and how this evolved over the last decade.
October 17, 2019
Video
Andrew Kuykendall, MD, discusses the background to the JAK2 inhibitor fedratinib (Inrebic), which was approved by the FDA in August 2019 for the treatment of patients with intermediate-2 or high-risk primary or secondary myelofibrosis, including post–polycythemia vera or post–essential thrombocythemia MF.